viernes, 4 de enero de 2019

T cell receptor-engineered T cells for leukemia immunotherapy | Cancer Cell International | Full Text

T cell receptor-engineered T cells for leukemia immunotherapy | Cancer Cell International | Full Text



Cancer Cell International

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International201919:2
  • Received: 6 September 2018
  • Accepted: 24 December 2018
  • Published: 

Abstract

At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy is an effective option for leukemia therapy. Recently, T cell immunotherapy studies have mainly focused on chimeric antigen receptor- and T cell receptor-engineered T cells. Clinical trials involving chimeric antigen receptor-engineered T cells have been a major breakthrough and became a novel therapy for leukemia. As another potential therapy for leukemia, clinical application of TCR-engineered T cells remains in its infancy. This article presents a review of the current status of anti-leukemia immunotherapy using leukemia antigen-specific TCR-engineered T cells.

Keywords

  • T cell receptor-engineered T cells
  • Immunotherapy
  • Leukemia

No hay comentarios:

Publicar un comentario